Cancer mutations lead to the production of mutated proteins from which can be processed and 22 presented to CD8 + T cells as neoantigens. Despite the promise of immunotherapy targeting 23 neoantigens, which mutant peptides are likely to induce immune responses remain elusive. Here, we 24 determined two sets of MHC-I bound neoantigen structures and performed bioinformatics investigation 25 based on neoantigen data. Structural and bioinformatic analyses reveal that some types of mutations in 26 immunogenic neoantigens are preferentially selected. We also developed a strategy to expand the usage 27 of a known neoantigen by scanning potential MHC alleles. Overall, our results will extend the ability to 28 discover neoantigens that may be useful for cancer immunotherapy.
with the MHC. Thus, in this case, the KRAS mutation shows the likelihood that anchor mutated 166 neoantigens will exist to stimulate T cells.
167

Structural basis of non-therapeutic mouse neoantigen DPAGT1 V213L in complex with H-2 Kb
168
Having verified that the P3D residue of KRAS G12D neoantigens plays an important role in formation 169 of the pMHC complex, we studied whether other cancer neopeptides with anchor mutations had similar 170 properties. One such neopeptide, which is not immunotherapeutic, is the mutation of the C terminal 171 amino acid anchor residue of the mouse mutant DPAGT1 V213L peptide (7) . To study this we solved 172 the structure of mouse MHCI H-2 Kb in complex with mutant DPAGT1 V213L 8mer peptide 173 (SIIVFNLV, mutation site is indicated with the amino acid underlined) and the wild type 8mer 174 counterpart (SIIVFNLL) (Supplementary Table 3 ). The last residue of the peptide, a valine in the wild 175 type 8mer peptide (wt8mV) was replaced by leucine in the mutant 8mer peptide (mut8mL). Soluble 176 complexes of Kb-wt8mV and Kb-mut8mL were separately expressed, refolded and purified for 177 crystallization trials. Crystal diffraction data of Kb-wt8mV and Kb-mut8mL are processed to 2.4 Å and 178 2.5 Å resolution respectively ( Supplementary Table 3 ) and provides unambiguous electron density for 179 each peptide ( Supplementary Fig.1a ).
180
The overall structure of the Kb-wt8mV complex closely resembles that of Kb-mut8mL with the 181 exception of a slight difference at PΩ (P8) ( Supplementary Fig.1b ). The C-terminal PΩ residue acts as 182 an anchor in both the Kb-wt8mV and Kb-mut8mL complexes ( Supplementary Fig.1b ). Moreover, both 183 PΩ valine and leucine were preferably selected by H-2 Kb in a peptide library analysis (Supplementary 184 Fig.1c ). Both of the PΩ residues formed hydrogen bonds with Asp77, Tyr84, Thr143 and Lys146 of Kb 185 but the side chain of leucine in the mut8mL peptide is insert more deeply into Kb than valine in wt8mV 186 peptide because of longer side chain of the Leucine residue. Thus, P8L is able to make Van der Waals 187 contact with Tyr116 on the floor of the F pocket ( Supplementary Fig.1d, e ). These alterations did not 188 significantly affect the formation of peptide/Kb complex and change the TCR binding surface, 189 suggesting that, as far as T cell recognition is concerned the mut8mL neoantigen would be treated as a 190 "self-peptide", thus minimizing mut8mL neoantigen immunogenicity in vivo. All these indicate the 191 wild type and mutant DPAGT1 V213L peptides interact with Kb in a similar way, thus the mutation 192 might provide neither a higher concentration of peptide/Kb on the cell surface nor a TCR interface that 193 differs. This is unlike the case of the KRAS G12D mutant peptides which appear to interact more intensively with HLA, via the mutant acid residue P3D interaction with basic residues in the B pocket 195 of C*08:02, versus than the wild type counterpart.
196
Taken together, all these suggest that whether wild type or mutant amino acids at anchor positions 197 interacted differently with relevant HLA alleles might be key to neoantigen immunogenicity. 
210
We also gathered 11739 non-immunogenic neopeptides (peptides splice from mutant proteins) from 13 211 published papers termed raw non-immunogenic neopeptide dataset (RNND). All of these mutant 212 peptides were tested in in vitro T cell assays or clinical trials and did not elicit effective immune 213 responses. Notably, the vast majority of them were not the minimal peptides known to induce CD8 + T 214 cells response (most of them are 25mer peptides). Thus, we use the prediction algorithm NetMHCpan 215 4.0(40) to predict the conventional minimal length (9mers and 10mers) non-immunogenic neopeptides 216 with relevant HLAs under a cut-off IC50=500 nM. This dataset was termed non-immunogenic 217 neopeptide dataset (NND). This dataset contains 2883 putative entries. It turns out that many 218 neoantigens predicted to bind patients' HLAs very well are experimentally tested to be non-219 immunogenic and do not have the ability to evoke effective immune response. This fact compromised 220 the usage of predicting immunogenic neoantigen through prediction of neoantigen binding to patients'
221
HLAs.
223
Evident differences of mutation distribution between immunogenic and non-immunogenic
224 peptides 225 It is thought that immunogenic neoantigens would bind MHC well and the mutations in the 226 immunogenic neoantigens could increase the affinity for binding MHC. With our immunogenic 227 neoantigen data collected, we preformed binding prediction (NetMHCpan 4.0) of wild type and mutant 228 peptides in IND and showed the distribution of affinity ratio between them ( Fig.3a ). About 25.5% of 229 immunogenic neoantigens shows the predicted binding affinity above 500nM and about 24% do not 230 exhibit increased prediction binding affinity (WT/MUT affinity ratio <1). Thus, more characters of 231 immunogenic neoantigens which could help immunogenic neoantigen predictions are needed.
232
It is suspected that the position in the peptides of mutated amino acids could affects the 233 immunogenicity of neoantigens. To further investigate the mutation distribution at each peptide 234 position between immunogenic and non-immunogenic data, we calculated the mutation occurrence 235 frequency at each position of 9mer and 10mer peptides. Interestingly, both immunogenic 9mer and 236 10mer neoantigens show frequency fluctuation at each position with their mutations. The fluctuation of 237 non-immunogenic 9mer and 10mer neoantigens seems not as high as those from immunogenic dataset 238 ( Fig. 3b ; Supplementary Fig. 2 ). However the difference is not reaching significance probably due to 239 the limited size of so far available immunogenic data. Mutations in 9mer neoantigens were more 240 frequent at P2, P4, P5 and P8 position and relatively lower frequency at P3 and P7 positions, relative to 241 non-immunogenic 9mer data ( Fig. 3b ). Conceptually, when bound to HLA, peptides usually use P2 and 242 PΩ as anchor residues and use P4, P5 and P8 to contact TCR. Other residues in the peptide may contact 243 with MHC but usually contribute less to the affinity of the peptide-HLA interaction(41). Also to be 244 taken into this account is the fact that our structural studies above also show that mutations at anchor 245 positions can evoke effective immune responses. Thus, these observations enlightened us to classify the 246 mutation based on whether it located on the anchor (contribute primary binding force to MHC), MHC 247 contact (contact MHC but contribute much less for binding MHC) or TCR contact positions for further 248 study.
249
To find out the mutation location (anchor, MHC contact position and TCR contact position) of each 250 peptide in IND an NND respectively, a strategy was developed to define the mutations location of 251 neoantigens by combining the SYFPEITHI database(42), antigen binding motif from NetMHCpan(40) 252 and solved pMHC structures from Protein Data Bank (see Methods). We chose 9mer length of 253 neoantigens to do these studies since 9mer peptides are most frequent in both the IND and NND 254 collections. Peptides bound to MHC alleles for which structure models were not available in PDB were 255 excluded from these analyses.
256
The 9mer neoantigens (or neopeptides) with mutations from IND and NND were divided into three 257 functional classes based on the following: anchor mutation, MHC contact position mutation or TCR 258 contact position mutation ( Fig. 3c ). After calculating the frequency of each class, we found that the 259 immunogenic neoantigens were significantly more likely than NND to express mutations at TCR 260 contact region ( Fig. 3d, p<0 .05, Z-test) and less likely to include mutations at MHC contact regions 261 (excluding those at anchor positions) ( Fig. 3d, p<0 .01, Z-test). These results can partially support 262 proposals of others that neopeptides with TCR contact position mutation will preferentially be 263 immunogenic(7). However, the odds of mutations at the anchor positions were similar between INDs 264 and NNDs, therefore the importance of anchor position mutations in immunogenicity is not clear ( Fig.   265 3d). These results are consistent with our structural studies showed that the immunogenic neoantigen Supplementary Fig. 3 ). This could be due to the idea that 274 mutation to Leu and Tyr might supply good contacts with MHC to stabilize the binding of neoantigens 275 to MHC or good contacts with TCR to stimulate T cells. This is consistent with our previously studies 276 that Tyr is important in TCR-peptide/MHC recognition(43-46).
277
Next, to check the similarity between wild type and the mutant amino acids of neoantigens and non-278 immunogenic neopeptides, we defined similarity of those amino acids from IND and NND using the 279 normalized BLOSUM62 substitution matrix(47). In this matrix, bigger normalized score represents more similarity between the wild type and the mutant peptides. For the situation of immunogenic data 281 compare to non-immunogenic data, the peptides with immunogenicity did not shown significant 282 difference between wild type and the mutant amino acids ( Fig. 4a, p=0 .2077, student t-test). For the 283 situation of anchor mutated peptides, the similarity of immunogenic neoantigens to their wild type 284 counterparts turn out to be lower than the similarity of the non-immunogenic peptides (Fig. 4b,   285 p=0.001, student t-test). For the situation of 9mer peptides with TCR contact position mutation, similar 286 result occurs between immunogenic and non-immunogenic data (Fig. 4c, p=0 .019, student t-test). We 287 did not test for mutations at MHC contact regions, because the available data was too limited so far.
288
These results demonstrated that through the mutation position classification quantifiable amino acid 289 differences between mutation and their wild type counterparts do indeed exist at anchor and TCR 290 contact positions between immunogenic and non-immunogenic data.
291
To test whether the mutant peptides in IND are more preferentially presented by HLAs than wild type 292 peptides, we generated amino acids half-bits of each HLA from P1 to P9 (we test 9mer peptides only 293 due to their relatively abundant quantity) which present in IND, based on the binders collected from 294 IEDB (see Methods). Then, merged bits of mutated neoantigens and their wild type peptides with their 295 relevant HLAs were calculated respectively ( Fig. 4d-f ). To our knowledge, peptide with higher merge 296 bits means preferentially presented by HLA. We first tested peptide merge bits in all 9mer neoantigens 297 and their wild type counterparts. The higher merged were shown in mutant neoantigens compare to 298 their wild type counterparts, which means immunogenic neoantigens more likely to be presented by 299 their relevant HLAs ( Fig. 4d, p=0 .0088, student t-test). We next tested this character from the data of 300 9mer anchor mutated neoantigen and 9mer TCR contact position mutated neoantigen. Surprisingly, 301 anchor mutated neoantigen showed significantly higher preference to be present by their relevant HLAs 302 than their wild type counterparts ( Fig. 4e , ****p<0.0001, student t-test), while TCR contact position 303 mutated data did not shown any significance (Fig. 4f, p=0 .9358, student t-test). From above results, it is 304 evident that mutations of immunogenic neoantigens in the anchor positions and in the TCR contact 305 positions shows different characters and should be studied separately. Moreover, the mutations of 306 immunogenic neoantigens in the anchor positions were needed for further studies.
307
Inspired by our structure studies of two sets of anchor position mutated neoantigens, we therefore 308 decided to find out how the mutations and wild type amino acids in immunogenic neoantigens were 309 related to the known residue preferences of different HLA alleles, and whether the associations were similar for immunogenic and non-immunogenic peptides. The cut-off for preferential amino acids was 311 applied to be above 10% (include 10%) as described previouslly(48) based on the data from peptide 312 library ( Supplementary Fig. 4 ). Neoantigen mutations changes from wild type to mutant at anchor 313 positions were divided into 4 types: non-preferential to non-preferential residues (N to N), non-314 preferential to preferential residues (N to P), preferential to non-preferential residues (P to N) and 315 preferential to preferential residues (P to P) ( Supplementary Table 5 ). Mutations at MHC contact 316 position mutation were not examined because, as above, the numbers of these types of mutations were 317 too small to achieve statistical significance. Mutations at TCR contact regions was also not examined 318 because no residue preferences were found at these sites (see above).
319
We analyzed the proportion of these 4 types of mutation in the immunogenic and non-immunogenic 320 datasets respectively. Interestingly, almost all (26 in 27) of the immunogenic neoantigens appear to be 321 in the class of N to P preference ( Supplementary Table 5 ; Fig. 4e ). Statistical analysis shown that the N 322 to P preference frequency of immunogenic neoantigens with mutations at anchor positions was 323 significant higher ( Fig. 4e, p<0 .001) than that for non-immunogenic neoantigens'. The other classes of 324 preference did not show significant differences between the immunogenic and non-immunogenic 325 neoantigens. Analyzing our results in more depth we found that one immunogenic neoantigen,
326
MYADM, in the immunogenic peptide collection did not follow the N to P preference at its C-terminal 327 binding site for MHC. However, the original paper describing this immunogenic neoantigen showed 328 that both the wild type and the mutant peptides of MYADM could elicit self T cell responses(49), 329 suggesting that the wild type peptide, with its C terminal anchor, was binding the patient's MHC 330 protein and immunogenic anyway. Thus, this neoantigen may not be a good target for further clinical 331 trial and can be regarded as an exception in our study.
332
With the classification of 4 types of neoantigen mutations changes at anchor positions, 96% (100% if 333 the exception MYADM is not counted) of the immunogenic neoantigen mutations belong to the class of 334 N to P preference and our detailed study of the KRAS G12D therapeutic neoantigen with the mutation 335 from the non-preferential residue G to the preferential residue D (N to P) is one of the clear examples.
336
That is, neoantigens with mutations at anchor positions not belonging to the class of N to P preference 337 would be very unlikely to be immunogenic and our detailed study of the DPAGT1 V213L non-338 therapeutic neoantigen with the mutation from preferential residue V to the preferential residue L is one 339 of the clear examples. Thus it could be a clear indicator for the exclusion of non-immunogenic neoantigen in the process of neoantigen prediction. From our NND dataset containing non-341 immunogenic neopeptides predicted to bind relevant HLAs, about 42% of non-immunogenic 342 neoantigens with mutations at anchor positions were not N to P preference and could be eliminated 343 during immunogenic neoantigen prediction with this indicator (Fig. 4f ). Thus, we suggest that the 344 processes we describe here could greatly help prediction of functional neoantigens for cancer 
353
Our strategy to identify new HLA candidates is divided into four steps. First, phylogenetic analysis was 354 performed for the 15 different HLA-C alleles with relatively high frequency in human(50)
355
( Supplementary Table 6 ; Supplementary Fig. 5 ). In the phylogenetic tree, three alleles (C*07:01, 356 C*07:02 and C* 17:01) were distantly related to the reference allele, C*08:02, and were excluded from 357 further analyses ( Supplementary Fig. 5 ). The relative distance of the remaining alleles to C*08:02 was 358 calculated based on the phylogenetic tree. Secondly, their relative distance from C*08:02 was 359 normalized as shown on the heatmap (Fig. 5a ). This showed that C*05:01 is closely related to C*08:02 360 and might therefore be able to present the KRAS neoantigen. Third, sequence alignment combined with 361 structure analyses was used to compare HLA-C*08:02 and other HLA-C alleles. Comparison of P3 and 362 PΩ binding motif of HLA-C alleles shown that C*05:01 is the only allele have the same sequence as 363 C*08:02 at its P3 anchor binding motif ( Supplementary Table 7 ; Supplementary Fig. 6 ). Moreover 364 C*05:01 differed from C*08:02 by only two amino acids (at positions 77 and 80 on the α1 helix) at its 365 PΩ binding motif. Because of these observations we decided to test whether the changes would affect 366 the ability of C*05:01 to present the KRAS G12D peptide. We performed structural analyses based on 367 our solved HLA-C*08:02 structure (C08-mut9m).
368
Three residues from HLA -C*08:02 (position 97, position 99 and position 156) bind P3 of the peptide.
Two of these are arginine amino acids which promote engagement of the peptide acidic residue ( Fig.   370 5b; Supplementary Table 7 ) and thus may play important roles in presenting acidic P3 mutated 371 neoantigen. These three amino acids are the same in C*05:01. The PΩ of peptide contacts amino acids 372 77, 80, 84, 143 and 146 in C*08:02 (Fig. 2c ). Three of these (positions 84, 143, and 146) are invariable 373 in most HLA-C alleles ( Supplementary Table 7 ). The two amino acids at positions 77 and 80 are also 374 the same in many of the HLA-C alleles but C*05:01 and several other HLA-C alleles differ from 375 C*08:02 by S77N and N80K. Amino acids at these positions pointed toward the TCR region and 376 peptide respectively (Fig. 5c ). However, these five residues may not affect the presentation of peptides 377 which use leucine as a c-terminal residue because, regardless of the amino acids they express at these 378 five positions, most of HLA-C alleles select leucine as a preferential residue at the PΩ position of 379 peptide ( Supplementary Fig. 4 ). Thus, after these structural comparisons of HLA-C*05:01 and HLA-380 C*08:02, we inferred that HLA-C*05:01 might also present mutant KRAS G12D peptide and therefore 381 might be of potential use for T cell-based immunotherapy. We came to this conclusion in spite of the 382 fact that peptide binding predictions suggest that HLA-C*05:01 would bind with only low affinity to 383 both KRAS G12D 9mer and 10mer mutated peptides ( Supplementary Table 2 ).
384
We next evaluated whether KRAS G12D can really be presented by C*05:01. We expressed C*05:01 385 heavy chain and 2M in E. coli and refolded them with 4 peptides: GADGVGKSA (mut9m, mutation 386 site is indicated with the amino acid underlined); KRAS G12D 10mer peptide GADGVGKSAL 387 (mut10m); wild type KRAS G12D 9mer peptide GAGGVGKSA (wt9m) and KRAS G12D 10mer 388 peptide GAGGVGKSAL (wt10m). Only the mutant KRAS G12D 10mer peptide successfully refolded 389 with HLA-C*05:01, suggesting that HLA-C*05:01 and HLA-C*08:02 are partially differ in their 390 antigen presentation abilities. We solved the crystal structure of C*05:01 in complex with the KRAS 391 G12D 10mer peptide to a resolution of 1.9 angstroms ( Supplementary Table 3 ). High quality resolution 392 and electron density maps shown reliable placement of the 10mer peptide in C*05:01 complex ( Fig.   393   5d ). The TCR contact positions P5, P6, P7 and P9 of the peptides are flexible and can't form stable 394 conformations (Fig.5e ). Nevertheless, the structure of the C05-mut10m closely resembles that of C08-395 mut10m at the P1-P4 peptide region ( Fig. 5e-g) . Overlay of the C05-mut10m and C08-mut10m peptide 396 regions shows that an exception occurs at the P5-PΩ region of the peptides and position 77 and 80 of 397 the HLA proteins (Fig. 5e ). The peptide P8S positions in both the C05-mut10m and C08-mut10m act 398 as axillary anchors. Differences also occur at the P10L position. Although C*05 and C*08 differ at position 77, the Asn77 of C05 and the Ser77 of C08 form hydrogen bonds with P10L in a similar way.
400
However, Asn80 from C*05 binds the oxygen of P10L while Lys80 from C*08 does not with the 401 oxygen of P10L shifting towards the a2 helix and thus losing one of the hydrogen bonds from Tyr84 402 ( Fig. 5h) . These results explain to some extent why the GADGVGKSA (mut9m) peptide did not 403 successfully refold with C*05:01. The most likely cause is the change at position 80, which will 404 weaken the interaction between the 9mer peptide and C*05:01, thus reducing the likelihood of forming 405 a stable complex. Excluding these differences, the peptide binding grooves of the HLA-C proteins had 406 relatively conserved interactions with the KRAS G12D 10mer peptide. It is, however, possible that 407 position 80 is located in the interface of the pMHC and T cell receptor, and there may change the 408 morphology of the epitope and impact T cell selection.
409
In line with our hypothesis, the structure of HLA-C*05:01 in complex with KRAS G12D indicates that 410 C*05:01 can also present the KRAS G12D neoantigen but in a slightly different way than C*08:02 411 does. Therefore HLA-C*05:01 might also be a potential target for T cell-based cancer immunotherapy.
413
An optimized procedure of neoepitope prediction 414 Nowadays, most in silico neoepitope (neoantigen and corresponding HLAs) prediction methods have 415 used neopeptide binding affinity to discover neoantigens for cancer immunotherapy. Although binding 416 to MHC-I is currently the most popular computational filter for removing nonantigenic neopeptides, it 417 still not robust enough to eliminate most of these candidates.
418
Our results emphasize the importance of anchor mutated neopeptides in cancer immunotherapy. We 419 demonstrated that almost all of anchor mutated neoantigens which have induced autologous T cell 420 response and are clinically effective have a mutation the demonstrates an N to P preference at anchor 421 positions. Thus, we suggest an optimized procedure that will improve the accuracy of neoepitope 422 prediction methods. The workflow of this procedure is shown in Fig. 6a . Tumor and normal samples 423 are first obtained from cancer patient for genomic DNA and RNA sequencing and tumor infiltrating 424 lymphocytes (TILs) isolation. Whole-exome sequencing analysis allows discovery of somatic 425 mutations present in the tumor cells, but not in normal cells. In silico binding prediction is performed 426 and can output a list of candidate peptides. The novelty of our procedure is in the following steps.
427
Neoantigen candidates will be classified into 3 types: MHC anchor mutation (contact MHC and is vital for binding MHC), MHC contact position mutation (contact MHC but contribute much less) or TCR 429 contact position mutation. Each type may use a different filtration strategy during neoantigen candidate 430 prediction (Fig. 6b ). This procedure may eliminate at least 42% of the anchor position mutated 431 candidates. Also, the similarity score could be used to help judge the possibility that the TCR contact 432 position mutated neopeptides will be immunogenic. These candidates can be further tested in vitro and by HLA-C*0802. We found that the G12D mutation in these neoantigens (9mer and 10mer) drive 442 intensive interactions to MHC via acting as an unconventional anchor residue. This observation of the 443 mutation at the anchor position which cause the epitope to be immunogenic illustrates the complexity 444 of neoantigens beyond the previous evidences that mutations which were solvent-exposed and 445 therefore accessible to TCRs were more likely to be immunogenic. We next studied the structure of a 446 non-immunogenic neoantigen, DPAGT1 V213L discovered from previously publication(19). Although 447 this peptide also had a mutation at the anchor position, it did not change the conformation of the TCR 448 contact region. Thus different types of mutations in the anchor position of neoantigens would lead to 449 different fates for immunogenicity.
450
To expand our findings more broadly and deeply we combined our structural work with the (19, 20, 51, 52) . These assignments took into account the fact that the peptide 461 anchor amino acids differ according to MHC allele with which they are engaged and the MHC anchor 
467
which is always reactive no matter it has the mutation or not, was not counted). Thus this indicator are 468 clear and practical for identifying anchor mutated neoantigens, called as "Non-preferential to 469 Preferential Conversion (NPC)". The amino acid turning from non-preferential to preferential may 470 create a new epitope which never seen by self-immune system. Given the fact that during the prediction 471 of viral antigen, most amino acids in the peptide are different from self-peptide, such indicator above is 472 not necessary for consideration. Hence, we believe NPC is an effective supplement indicator to 473 eliminate non-immunogenic peptides from cancer mutaome in silico.
474
The way of neoantigen study and the rules for immunogenic neoantigens could be very different with 475 normal antigens. Neoantigens are the altered-self between self-peptides and totally different foreign On a related subject, here we tackled the issue of whether MHC alleles other than C*08:02 might be 488 useful in presenting the common KRAS G12D mutation as a neoantigen. We found that an MHC allele 489 that is closely related to C*08:02, C*05:01 might be such a possibility. Our structural work showed that 490 C*05:01 could indeed bind the KRAS G12D 10mer peptide and the configuration of the structure we 491 observed was quite similar to that of the same peptide bound to C*08:02. Thus, KRAS G12D mutation 492 could also be a good neoantigen in HLA-C*05:01 positive patients and the strategy we used to discover 493 this could be used to help enlarge knowledge of other suitable HLA alleles thus increasing the size of 494 the patient population in which such neoantigens could be used.
495
Our data suggest three possible immunogenic neoantigen models ( Supplementary Fig. 7) . Model A 496 represents the situation which peptide mutation occurs at TCR contact region and therefore appears 497 directly foreign to T cells. In this case, the neoantigens might be strongly immunogenic if the 498 corresponding wild type peptide is greatly dissimilar at the mutated site. Important differences might be 499 amino acid properties such as hydrophobicity, charge and polarity. Model B represents the situation in 500 which peptide mutation occurs at an MHC contact region (not including anchor sites). We found that 501 mutations at these sites are less likely to render the neoantigen immunogenic. However, our curated 502 data did show some bias for mutation at such regions, due to the relatively limited sample size 503 available now for this category, the relationship for such between mutation and immunogenicity is not 
508
Overall, more structural and biochemical experiments, with inclusion of more MHC alleles are needed 509 to improve bioanalytical predictive power in the important search for useful cancer neoantigens to treat 510 these devastating diseases. We hope the methods proposed here will help guide such future studies. 
514
This study was designed to use x-ray crystallography to examine the difference between immunogenic and non-immunogenic mutant peptides bound to MHCI. On the basis of these results, we also took somatic mutations and their corresponding HLA class I alleles that reported to elicit T cell response in 573 humans. Those tumor neopeptides with uncertain response or not provided with minimal sequence 574 were not collected in our dataset. Each entry includes following information: tumor type, gene symbol, 575 wild type/ mutant peptide sequence, wild type/mutant peptide predicted binding affinity(31), single 576 amino acid change, HLA allele, and PubMed ID from NCBI.
577
For non-immunogenic dataset NND, we collected 11739 peptides (not the minimal peptide) from Amino acid half-bit log-odds score in every position for different HLA alleles was calculated as described by Morten et al(59) . Briefly, frequency of amino acid on distinct position was firstly 600 computed using Hobonm 1 algorithm to decrease the weight of similar sequence before calculation.
601
It is worth to note that, in some cases, if the sample size is too large, it may include similar sequences, 602 even duplicate sequences. Thus, clustering should be performed at first. For example, if one cluster 603 include 10 similar sequences, the weight of every sequence in this cluster will be 1/10. The similarity 604 score was the maximum percent of the same amino acids between one current sequence and every 605 sequence in one cluster, and the threshold of default similarity to decide whether current sequence 606 belongs to a cluster is 0.63.
607
In other cases, small sample related to amino acid depletion. Thus, we make use of pseudo counts to 608 solve this problem. The formula to calculate the pseudo counts is
is the real frequency of the amino acid j and | is frequency of amino acid i replace amino 611 acid j based on BLOSUM62 matrix(47).
612
After that, the estimated frequency is calculated according to equation
where α is the number of clusters subtracted by one. The default value β is 200.
615
Next, the half-bit log odds score is defined as
617
where is the background frequency of amino acids. In our case, an equiprobable background amino 618 acid distribution is used.
619
The merged half-bits of one peptide is the summing half-bit score of amino acids in this peptide.
620
Statistical test of wild type peptides and mutant peptides merged half-bits from IND were tested using 621 t-test.
622
Nonameric peptide library obtained, peptide library sequence logo generation and HLA anchor 624 position preferential determination
625
The nonameric peptide library of 30 HLA alleles was downloaded from IEDB(60). Sequence logos 626 were generated base on peptides library using the sequence logo generator(61). Threshold for 627 preferential amino acids at anchor position of each HLA alleles was applied to be above 10%(48)
628
(include 10%) based on the data from nonameric peptide library. 
637
For display the allele similarities on the heat map, we read the phylogenetic tree using R package ape, 
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